Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Controlled Trial on Extinction of Opioidergic Binge Eating Disorder (BED) With Intranasal Naloxone Administration

Next Previous
Trial Profile

Clinical Controlled Trial on Extinction of Opioidergic Binge Eating Disorder (BED) With Intranasal Naloxone Administration

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naloxone (Primary)
  • Indications Binge-eating disorder
  • Focus Therapeutic Use

Most Recent Events

  • 15 Jun 2017 According to an Opiant Pharmaceuticals media release, the study results are expected to be independently published in a scientific journal.
  • 27 Mar 2013 Results will be presented at the 166th Annual Meeting of the American Psychiatric Association.
  • 03 May 2012 Primary endpoint 'Binge-frequency' has been met.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top